Cryoport (CYRX) Q2 2024 earnings summary

Executive summary

• Q2 2024 total revenue was $57.6 million, up 1% year-over-year, with commercial cell and gene therapy revenue rising 51% year-over-year and 20% sequentially, supporting 684 global clinical trials, including 76 in Phase 3.

• Services accounted for 66% of total revenue in Q2 2024, up from 62% in Q2 2023, while Life Sciences Products revenue declined 10% year-over-year.

• Cost reduction and capital realignment initiatives are expected to yield $22 million in annualized savings, with full implementation by year-end and a return to positive adjusted EBITDA in 2025.

• Net loss for Q2 2024 was $78–$80 million, primarily due to a $63.8 million impairment loss related to MVE Biological Solutions.

• Management anticipates a broad market recovery for life sciences, excluding China, and expects new services and products to diversify revenue streams.

Financial highlights

• Life Sciences Services revenue grew 8–8.1% year-over-year to $38.0 million in Q2 2024; Life Sciences Products revenue declined 10–10.4% to $19.6 million.

• Gross margin for Q2 2024 was 43.7%, up from 43.4% in Q2 2023.

• Adjusted EBITDA for Q2 2024 was negative $3.8 million, compared to negative $1.3 million in Q2 2023.

• Cash, cash equivalents, and short-term investments totaled $427.1 million as of June 30, 2024.

• Net loss per share for Q2 2024 was $1.62, compared to $0.42 in Q2 2023.

Outlook and guidance

• Full-year 2024 revenue guidance is $225–$235 million, with sequential revenue improvements expected through the remainder of 2024 and into 2025.

• Cost reduction and capital realignment measures targeting $22 million in annualized savings are expected to be fully implemented by year-end.

• Management targets a return to positive adjusted EBITDA in 2025, achievable even with modest revenue growth.

• Life Sciences Products demand is expected to remain soft until excess capacity is absorbed; China market is expected to remain challenged through 2025.